Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TSCAN THERAPEUTICS, INC.

(TCRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
5.05(c) 4.85(c) 4.83(c) 4.72(c) 4.61(c) Last
26 206 14 176 13 065 10 229 11 861 Volume
+10.75% -3.96% -0.41% -2.28% -2.33% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 11,3 M - -
Net income 2021 -49,1 M - -
Net cash position 2021 3,90 M - -
P/E ratio 2021 -0,48x
Yield 2021 -
Sales 2022 12,4 M - -
Net income 2022 -72,0 M - -
Net cash position 2022 15,1 M - -
P/E ratio 2022 -0,74x
Yield 2022 -
Capitalization 110 M 110 M -
EV / Sales 2021 9,33x
EV / Sales 2022 7,62x
Nbr of Employees 93
Free-Float -
More Financials
Company
TScan Therapeutics, Inc. (TScan), along with its wholly owned subsidiary, TScan Securities Corporation is a biotechnology company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients... 
More about the company
All news about TSCAN THERAPEUTICS, INC.
01/1217,271,699 Common Stock of TScan Therapeutics, Inc. are subject to a Lock-Up Agreement ..
CI
01/12Certain Stock Options of TScan Therapeutics, Inc. are subject to a Lock-Up Agreement En..
CI
01/10TScan Outlines 2022 Priorities as Programs Enter Clinic
AQ
01/10TScan Therapeutics, Inc. Plans to Begin its First Clinical Trials This Year 2022
CI
2021HC Wainwright Starts TScan Therapeutics at Buy With $21 Price Target
MT
2021TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hemat..
GL
2021TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hemat..
GL
2021TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annu..
GL
2021Boston Properties Signs Three Leases at Waltham, Massachusetts, Life Sciences Project
MT
2021TSCAN THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
2021TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cel..
GL
2021TScan Therapeutics, Inc. Completes the Construction of GMP Manufacturing Facility to Ma..
CI
2021TScan Therapeutics to Participate in Upcoming Investor Conferences
AQ
2021TSCAN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2021TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent C..
PU
More news
News in other languages on TSCAN THERAPEUTICS, INC.
01/10TScan Therapeutics, Inc. prévoit de commencer ses premiers essais cliniques cette année..
2021TScan Therapeutics nomme Zoran Zdraveski au poste de directeur des affaires juridiques
More news
Analyst Recommendations on TSCAN THERAPEUTICS, INC.
More recommendations
Chart TSCAN THERAPEUTICS, INC.
Duration : Period :
TScan Therapeutics, Inc. Technical Analysis Chart | TCRX | US89854M1018 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 4,61 $
Average target price 21,50 $
Spread / Average Target 366%
EPS Revisions
Managers and Directors
David P. Southwell President, Chief Executive Officer & Director
Brian Michael Silver Chief Financial Officer
Timothy Joseph Barberich Chairman
Gavin MacBeath Chief Scientific Officer
Ittai Harel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TSCAN THERAPEUTICS, INC.2.44%110
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508